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Stem cell differentiationesistance ABC transporters has been suggested as a functional marker and
chemoprotective element in early human progenitor cell types. In this study we examined the expression and
function of the key multidrug-ABC transporters, ABCB1, ABCC1 and ABCG2 in two human embryonic stem
(HuES) cell lines. We detected a high level ABCG2 expression in the undifferentiated HuES cells, while the
expression of this protein signiﬁcantly decreased during early cell differentiation. ABCG2 in HuES cells
provided protection against mitoxantrone toxicity, with a drug-stimulated overexpression of the transporter.
No signiﬁcant expression of ABCB1/ABCC1 was found either in the undifferentiated or partially differentiated
HuES cells. Examination of the ABCG2 mRNA in HuES cells indicated the use of selected promoter sites and a
truncated 3′ untranslated region, suggesting a functionally distinct regulation of this transporter in
undifferentiated stem cells. The selective expression of the ABCG2 multidrug transporter indicates that
ABCG2 can be applied as a marker for undifferentiated HuES cells. Moreover, protection of embryonic stem
cells against xenobiotics and endobiotics may depend on ABCG2 expression and regulation.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionHuman embryonic stem (HuES) cells provide new hopes in the
clinical treatment of a number of diseases and, at the same time, they are
excellent models for physiological human cell differentiation. By now a
number of HuES cell lines are available, with well documented
characteristics to spontaneously differentiate into various progenitor
cell types, and even to fully differentiated tissues [1,2]. Adetailed analysis
of the expression and regulation of keymembrane proteins in HuES cells
may signiﬁcantly help our understanding of their functional properties
and should provide a basis for successful therapeutic applications.
In this study, by using two different HuES cell lines and their
differentiated offsprings, we have examined the expression and regula-
tion of three key human multidrug resistance (MDR) ABC transporters,
ABCB1 (MDR1/Pgp), ABCC1 (MRP1) andABCG2 (BCRP/MXR). These three
ABC transporters are widely accepted as the major components of a
xenobiotic/drug resistance system in our body, recently termed as
“chemoimmunity” defense network (see [3]). MDR-ABC transporters arells; MDR, multidrug resistance;
ODXL, podocalyxin XL; SSEA4,
resceine-isothiocyanate; APC,
i).
ll rights reserved.ATP-dependent active transporters, capable of extruding a large number
of hydrophobic andamphipathicmolecules fromselected cell types. They
provide defensemechanisms at the tissue barriers, including the gut, the
lung, the placenta, the blood–brain and the blood–testis barriers. The
wide and overlapping substrate recognition and extrusion by these ABC
transporters ensuresanefﬁcientprotectionof thecells and tissues against
chemical invaders [3].
In the literature, abundant expression of MDR-ABC transporters in
selectedprogenitor cell typeshas been suggested. Itwasﬁrstobserved in
hematopoietic progenitor cell preparations that a so called “side
population” (SP) of cells was less efﬁciently stained by the ﬂuorescent
Hoechst 33342 dye. These SP type cellswere found to be themost potent
bone marrow repopulating early hematopoietic stem cells, and by now
several reports indicate that such SP cells behave as multipotent stem
cells in a varietyof tissue sources [4–7]. Itwas found that the basis of this
SP feature is a high level expression of the ABCG2 protein (and probably
also the ABCB1/MDR1 protein), and their active Hoechst dye extrusion
function. Still, the physiological role of ABCmultidrug transporters in the
progenitor/stem cell function is unclear. Abcg2 and Abcb1a/b knock out
mice have no reduced stem cell number or function [8], and over-
expression of ABCG2 in monkey hematopoietic stem cells does not
interfere with hematopoietic repopulation and cell maturation [9,10].
However, ABCG2 overexpressed in human umbilical cord blood derived
early hematopoietic cells increased the number of clonogenic progeni-
tors and impaired the development of CD19+lymphoid cells, whereas
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been suggested that ABCG2 expression may be an important factor
under hypoxic conditions [12], and multidrug transporters may
signiﬁcantly contribute to stem cell protection against drugs or
xenobiotics [13]. There has been no detailed study reported as yet
about the expression and regulation of ABCG2 or other MDR-ABC
transporters in human embryonic stem cells, therefore we decided to
performsuch comparative expression studies in twoHuES cell lines, and
examine the three most relevant multidrug transporters.
In the present work we also aimed to characterize the regulation of
ABCG2 expression in the HuES cells at the mRNA level. The role of
different untranslated regions (UTRs) in the ﬁne-tuned regulation of
gene expression is already well appreciated [14,15]. Alternative
promoter usage, producing different 5′-UTRs, could be a result of
tissue speciﬁc gene expression proﬁle via the presence of different
transcription factor binding sites, and may also alter mRNA stability or
translation efﬁciency. Alternative polyadenylation sites, resulting in
the formation of different 3′-UTRs, modulate the stability of mRNA e.g.
through potential micro-RNA target sites.
In the case of ABCG2, the presence of transcriptional regulatory
elements was ﬁrst documented 5′ of exon 1 [16], while a recent report
showed different 5′-UTR variants in different cell types, indicating the
presence of alternative promoters [17]. The activity of the originally
described promoter results in the presence of exon 1b in the transcript,
whereas two other potential promoters result in the inclusion of either
exon 1a or exon 1c in the mRNA [17]. Recently, the mouse Abcg2 was
also found to be under the control of three distinct promoters, working
mutually exclusively during hematopoiesis: early progenitor cells
expressed only exon 1a containing transcripts, while in later phases of
erythroid differentiation only exon 1b and exon 1c sequences were
found in themRNA [18]. Therefore, in this studywehave also examined
the messenger RNA structure of ABCG2 in HuES cells.
2. Materials and methods
2.1. HuES cell culturing and differentiation
The human embryonic stem cell lines HUES9 and HUES1, having
normal karyotypes, were gifts from Dr. Douglas Melton, Harvard
University, and the cells were maintained according to the culture
protocol provided. Brieﬂy, cells were cultured on mitomycin-C treated
mouse embryonic ﬁbroblast feeder cells in complete HUES medium
consistingof 15%knockout serumreplacement (Gibco, Grand Island,NY),
80% knockout Dulbecco modiﬁed Eagle medium (KoDMEM, Invitrogen,
Carlsbad, CA), 1 mM L-glutamine, 0.1 mM beta-mercaptoethanol, 1%
nonessential amino acids, and 4 ng/mL human ﬁbroblast growth factor.
The differentiation of the HuES cells were initiated as follows:
undifferentiated cells at conﬂuence in 6-well plates were treated withFig. 1. Flow cytometry measurements of cell surface marker expression in undifferentiat
trypsinization. Non-viable cells were excluded by Topro3 or 7AAD staining. The remaining m
were used as markers of undifferentiated state. ABC transporters G2 and B1 were labeled w
absence of differentiation of HUES9 towards ﬁbroblasts. Dashed lines show staining with apcollagenase IV and were transferred to Poly (2 Hydroxyethyl-methacry-
late) (Sigma-Aldrich, St. Louis, MO) treated Petri dishes to allow
embryoid body (EB) formation. Cells were kept in differentiation
medium consisting of KoDMEM supplemented with 20% non heat-
inactivated fetal bovine serum (Invitrogen, Carlsbad, CA), 1% nones-
sential amino acids,1mM L-glutamine, and 0.1mMbeta-mercaptoetha-
nol for six days, the medium being changed daily. Under these
conditions, the HuES cells generated EBs which are complex, ter-
atoma-like tissue structures with highly variable forms and tissue
elements [19,20]. These EBs were placed onto gelatin-coated plates,
where they attached to the surface and continued a further spontaneous
differentiation process by forming recognizable tissue-types. Under
these conditions, formation of endothelial, epithelial, and neuronal cells,
as well as of ﬁbroblasts and cardiomyocytes could be observed. Cell
typeswere identiﬁed bymorphological signs under phase contrast light
microscopy, as well as by immunostaining for various protein markers.
Hematopoietic differentiation of HuES cells were induced by using
OP9 mouse stromal cells, as described previously [21].
2.2. Flow cytometry
Cells were prepared in PBS containing 0.5% bovine serum albumin,
and were labeled with a combination of monoclonal antibodies
(mAbs). In all samples an anti-mouse Sca-1 (Ly-6A/E) (FITC or PE, BD.
Pharmingen) antibody was employed, for gating out the positively
labeled mouse cells. For speciﬁc labeling we used the following
directly labeled anti-human antibodies: CD44-FITC, CD73-PE, CD90-
PE (BD. Pharmingen), CD34-PerCP (BD. Biosciences), PODXL-PE,
SSEA4-APC (R and D Systems).
Indirect staining of ABCG2 was performed by using the 5D3
monoclonal antibody, applied in the presence of FTC (Alexis Biochem-
icals), a speciﬁc inhibitor of ABCG2whichmaximizes 5D3 binding [22].
The monoclonal antibody MRK16 (Alexis Biochemicals) was used for
MDR1 labeling. Secondary antibodies were R-phycoerythrin conju-
gated goat anti-mouse IgG2b, and IgG2a (Molecular Probes), respec-
tively. Control staining with appropriate isotype-matched control
mAbs was included. Cells were incubated for 30 min at 37 °C with the
antibodies, and dead cellswere gated out based onTopro-3 or 7AAD (in
case of APC labeling) staining. Sampleswere analyzed bya FACSCalibur
ﬂow cytometer (Becton Dickinson Immunocytometry Systems [BDIS],
San Jose, CA) equipped with a 488 nm argon laser and a 635 nm red
diode laser with CellQuest acquisition software (BDIS).
2.3. Immunohistochemical and functional assays – confocal microscopy
For immunostaining, cellswere seeded onto eight-well Nunc Lab-Tek
II Chambered Coverglass (Nalge Nunc International, Rochester, NY), and
ﬁxed with 4% paraformaldehyde in Dulbecco's modiﬁed PBS (DPBS) fored HUES9 cells. Single cell suspension from HUES9 clumps was obtained by gentle
ouse feeder cells were excluded by using Sca-1-FITC labeling. SSEA4-APC and PODXL-PE
ith indirect method (see Materials and methods). CD44 was used to demonstrate the
propriate isotype-matched control mAbs.
Fig. 2. Flow cytometry analysis of cell surface marker expression in HUES9 cells during early stage of spontaneous differentiation. (A) Percentage of SSEA4+ and ABCG2+ cells as
determined by ﬂow cytometry in spontaneously differentiating HUES9 culture. Day 0 indicates undifferentiated HuES cells. Results of three independent experiments are shown. (B)
Representative ﬂow cytometric analysis of undifferentiated and partially differentiated HUES9 cells. Single cell suspension of HUES9 cells were stained with SSEA4-APC and ABCG2
antibodies (left panel). Control staining with appropriate isotype-matched control mAbs is shown in the right panel. Non-viable cells were excluded by 7AAD staining. The remaining
mouse feeder cells were eliminated using Sca-1-FITC labeling and gating.
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nonspeciﬁc antibody bindingwas blocked for 1 h at room temperature in
DPBS containing 2mg/ml bovine serum albumin,1% ﬁsh gelatin, 5% goat
serumand 0.1% Triton-X 100. The sampleswere then incubated for 1 h at
room temperature with monoclonal antibodies for stem cell markers,
Oct-4 (1:50 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), SSEA-4
(1:10 dilution, R and D Systems, Minneapolis, MN) or podocalyxin
(PODXL) (1:10, R and D Systems, Minneapolis, MN). After washing with
DPBS, the cells were incubated for 1 h at room temperature with Alexa
Fluor 488-conjugated goat anti-mouse IgG antibody. The cells were
stained for Nanog protein as described previously [23].
For cell surface labeling of ABCG2, the cells were gently washed with
Dulbecco's modiﬁed PBS (DPBS), and ﬁxedwith 1% paraformaldehyde in
DPBS for 15 min at room temperature, and then blocked for 1 h at room
temperature in DPBS containing 0.5% bovine serum albumin. The
samples were then incubated for 1 h at room temperature with the
monoclonal anti-ABCG2 antibody, 5D3, conjugatedwith Alexa Fluor 488,
diluted 5× in DPBS containing 0.5% BSA, and ﬁnally washed with DPBS.
Tric-phalloidin (Sigma-Aldrich, St. Louis, MO), in the ﬁnal con-
centration of 0.1 μg/ml was used for the detection of actin ﬁlaments,
while DAPI (Invitrogen, Madison, WI) was used for nuclear staining.
The stained samples were examined by an Olympus FV500-IX
confocal laser scanning microscope. All measurements were carried
out in four independent samples, at least in triplicate stainings.
2.4. Hoechst dye transport studies
Theblueﬂuorescencewas acquired at 405nmexcitation. The samples
were subjected to 1 μM Hoechst dye, and after a 120 s incubation, 1 μM
Ko143was added to themedium. Themultidrug resistance activity factor
(MAF) was determined from the steady state ﬂuorescence accumulation
rates before and after Ko143 addition [24–26].2.5. mRNA studies of the ABC transporters
RNA isolation was carried out by using Trizol® reagent (Invitrogen).
cDNA samples were prepared from 1 μg total RNA using the Promega
Reverse Transcription System Kit as speciﬁed by themanufacturer. mRNA
levels for ABCB1, ABCC1 and ABCG2 were determined by the SYBR Green
technology on a Light Cycler® 480 real-time PCR system (Roche),
according to the manufacturer's instructions; GAPDH was used as an
internal control. Primer sequences are the following:ABCG2-forward is 5′-
TACCTGTATAGTGTACTTCAT and ABCG2-reverse is 5′-GGTCATGA-
GAAGTGTTGCTA; ABCB1-forward is 5′-GCCTGGCAGCTGGAAGACAAATAC
and ABCB1-reverse is 5′-CCATACCAGAAGGCCAGAGCATAA; ABCC1-for-
ward is 5′-AGTGGAACCCCTCTCTGTTTAAG and ABCC1-reverse is 5′-
CCTGATACGTCTTGGTCTTCATC; GAPDH-forward is 5′-GAAGGT-
GAAGGTCGGAGTCAandGAPDH-reverse is 5′-GACAAGCTTCCCGTTCTCAG.
For investigating 5′- and 3′-UTR variants of ABCG2, speciﬁc PCR
primerswere designed to amplify theparticularmRNAvariants (see also
Fig. 7A and C). Sequences of primers for the 5′-UTR variants are as
follows: forward Fa (for exon 1a) is 5′-CAAACCCAGCTAGGTCAGACG,
forward Fb (for exon1b) is 5′-GCATCCTGAGATCCTGAGCC, forward Fc (for
exon 1c) is 5′-GATTTGGGCTGCTTTGCTTC, and the common reverse R
(on exon 2) is 5′-ACAGCTCCTTCAGTAAATGCCTTC. Primer sequences
used to examine the 3′-UTR variants were the following: common
forward F (on exon 15) is 5′-CAATGCAACAGGAAACAATCC, reverse R1 is
5′-ATACAAGCCAAGGCCACG, reverse R2 is 5′-TGTGCAACAGTGTGATGGC,
and R3 is 5′-CAGTTCCAAACCCTCAGCC. The 3′-UTR reverse primers all
hybridize to exon 16 and only R3 detects speciﬁcally the longer 3′
isoform (see also Fig. 7C).
For quantifying ABCG2 exon 1a variants, a speciﬁc TaqMan® assay
was designed for the 1a/2 exon junction sequence. In addition, Pre-
Developed TaqMan® assays were purchased from Applied Biosystems
for detecting the total ABCG2 mRNA pool and β2-microglobulin, the
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assays were run and analysed by the StepOne™ Real-Time PCR System
(Applied Biosystems), according to the manufacturer's instructions.
3. Results and discussion
3.1. HuES cell-differentiation markers and ABC protein expression
Undifferentiated HuES cells were grown as clumps on a mouse
feeder cell layer, and the expression of representative marker proteins
and selected ABC transporters was determined by ﬂow cytometry, in
situ microscopy, and quantitative PCR. Thereafter the HuES cells were
differentiated into various cell types, as described in the Materials and
methods section, and these cells were also analyzed for markers and
ABC transporter expression with the three different methods.
For ﬂow cytometry experiments the clumps of undifferentiated
HuES cells were gently disaggregated by trypsin treatment, and the
remaining mouse feeder cells in the marker analysis were gated out
based on their Sca1 positivity. Our preliminary experiments showed
that the mouse feeder cells were uniformly positive for this speciﬁc
marker, whereas the HuES cells showed no counterstaining with the
anti-Sca1 antibody applied (data not shown).
Fig. 1 documents the mean expression levels of two stem cell
surface markers (PODXL, SSEA4), a ﬁbroblast marker CD44, and that of
ABCG2 (measured by the 5D3 monoclonal antibody (mAb)) and
ABCB1/MDR1 (measured by MRK16 mAb) in the undifferentiated,
non-permeabilized HUES9 cells by ﬂow cytometry. As shown, these
cells were found uniformly positive for the expression of SSEA4, a cell
surface protein recently described to be the most sensitive marker for
an undifferentiated state of human embryonic stem cells [27]. In
addition, these cells were also found to be positive for PODXL, another
established marker of undifferentiated stem cells, and negative for
CD44 (for the detection of other, intracellular stem cell markers see
the sections below). Labeling with the 5D3 monoclonal antibody,
which reacts with an extracellular epitope of the human ABCG2
protein [7,28], reﬂects ABCG2 expression on the cell surface. By using
this antibody, a signiﬁcant expression and, according to gating
calculations, a variable, 40–60% positivity in the HuES cells was
observed. We found no signiﬁcant staining of the HuES cells by the
anti-ABCB1monoclonal antibody, MRK16 (reacting with a cell-surface
epitope of theMDR1 protein), which suggested that ABCB1 expression
is under the antibody detection level in these cells. There is no
available cell surface reactive antibody against human ABCC1, and by
using the sensitive anti-ABCC1 mAb, R1, in permeabilized cells, we
could not detect any appreciable expression of ABCC1 (data not
shown). Similar results were obtained when another representative
HuES cell line, HUES1 was examined (Supplementary Fig. 1A).
In the following experiments we analyzed marker expression by
ﬂow cytometry in the differentiated cell types derived from HuES
cells. Spontaneous differentiation is the most appropriate way to
study thewidest variety of differentiated cell types and to examine the
loss of pluripotencymarkers. However, cells from the embryoid bodies
(see Materials and methods) could not be properly suspended by
proteolytic methods without causing major cell destruction, thus we
have no ﬂow cytometry data for these cell types. On the other hand,
the changes of surface markers at the beginning of spontaneous
differentiation could bemeasuredwith another culturingmethod. The
undifferentiated HuES cells were kept on the MEF feeder cells without
passaging, which caused the cells to differentiate. Fig. 2A demon-
strates the almost parallel decrease of SSEA4 and ABCG2 expression at
days 2, 4 and 6. In addition, as shown by a double stainingmethod (Fig.
2B), during cell differentiation, ABCG2 was present mainly on cells
that still remained SSEA4 positive. We attempted to resolve the
connection between SSEA4 and ABCG2 expression but at this stage it
was not possible to conclude whether ABCG2 is expressed earlier or
later among the SSEA4 positive cells, since these cells are very difﬁcultto sort, clone or test for their in vivo pluripotency (for mouse abcg2
positive ES cells and chimera embryos see ref. [29]). Nevertheless, our
data suggest the use of ABCG2 as a potential marker for undiffer-
entiated pluripotent HuES cells.
The early differentiated cell types which examined in detail by the
ﬂow cytometry were ﬁbroblasts/mesenchymal cells, obtained after EB
differentiation, and hematopoietic precursor cells, obtained during
differentiation of the HuES cell on OP9 mouse stromal cells. As shown
in Fig. 3A, ﬁbroblasts/mesenchymal cells differentiated from HUES9
cells did not express the undifferentiated cell markers, while showed
the surface expression of the expectedmarkers, CD44, CD73 and CD90
[30]. There was a complete loss of ABCG2 expression in these cells, as
examined by the 5D3 mAb binding.
Fig. 3B also documents the changes in relevant cellular markers in
HuES cells during early hematopoietic differentiation, initiated by co-
culturing on OP9 mouse stromal cells. As shown, within one week of
differentiation, the HuES cells gradually lost the early undifferentiated
cell markers, while produced c-Kit (CD117) and CD34 positive cells
among the SSEA4 negative cells in increasing quantities. During this
differentiation the loss of ABCG2 expression was observed by 5D3
immunostaining. As shown in Panel C of Fig. 3, HuES cells expressing
the CD34 marker had no measurable staining with the ABCG2
antibody, further supporting the potential use of ABCG2 as an
undifferentiated HuES cell marker. Similar differentiation experiments
were carried out by using the HUES1 cell line, and these cells showed a
similar relationship between CD34 and ABCG2 staining (Supplemen-
tary Fig. 1B, C).
Based on these experiments we concluded that ABCG2 expression
is characteristic for the undifferentiated HuES cells, while this
expression is lost during progenitor cell differentiation. We could
not detect ABCB1 or ABCC1 expression in any of the undifferentiated
or partially differentiated cell types examined here.
In the following experiments we examined the differentiation
marker and ABC protein expression in HuES cells by using immuno-
ﬂuorescence in confocal microscopy. Although ﬂow cytometry results
canbeproperly quantitated, theyare usually less sensitive,moreover, cell
disaggregation and the presence of mixed HuES cells originating from
different (potentially already partially differentiated) clumps, can make
these studies in some aspects difﬁcult to interpret. Therefore the above
described expression studies were also carried out in situ, by immuno-
ﬂuorescence assays in confocal microscopy, and supplemented with
highly sensitive quantitative RT-PCR detection of the relevant messages.
Fig. 4A documents the expression of the markers Oct4, SSEA4,
PODXL and ABCG2 in the undifferentiated clumps of HuES cells. All
these classical undifferentiated cell markers (and also Nanog-not
shown here) showed unequivocal positivity in the undifferentiated
clumps. Fig. 4B also shows non-permeabilized HuES clumps stained
with the anti-ABCG2mAb 5D3, indicating a strong plasma-membrane
staining of ABCG2 in the undifferentiated HuES cells (also documented
by the Supplementary Video).
Supplementary Fig. 2A shows a Z-stack scanning analysis of the 5D3
expression in the HUES9 cells, indicating a predominant membrane
staining in the middle sections of the clumps. Supplementary Fig. 2B
shows the pattern of the PODXL staining in a similar HUES9 cell clump,
indicating that this marker is predominantly present on the cell
membranes at the surface of the clumps (this localization difference
was seen in several similar experiments, in the case of both HuES cell
lines). Similarly to the ﬂow cytometry data, no immunostaining by the
anti-ABCB1mAb, MRK16, was observed by confocal microscopy in the
undifferentiated HuES cells (data not shown).
Confocal microscopy experiments were also carried out in various
EB-derived, differentiated forms of the HuES cells. As illustrated in
Supplementary Fig. 2C and 2D, no 5D3 staining was observed either in
ﬁbroblasts or cardiomyocytes (see Fig. legends).
In the following experiments we performed quantitative RT-PCR
studies in the undifferentiated state and in various differentiated
Fig. 3. Characterization of HUES9-derived differentiated cell types (A) Cell surface markers of HUES9d-F2 ﬁbroblast cells determined by ﬂow cytometry. Single cell suspension was
stained by the indicated antibodies. Non-viable cells were excluded by Topro3 or 7AAD staining. Dashed lines show staining with appropriate isotype-matched control mAbs. (B)
Percentage of SSEA4+, ABCG2+, CD34+ and CD117+ cells as determined by ﬂow cytometry in HUES9/OP9 co-culture at days 0 and 5. The percentage of CD34+ and CD117+ cells on day
5 were calculated from the SSEA4-population. (C) Representative ﬂow cytometric analysis of differentiating HUES9 cells at days 5 of hematopoietic differentiation. Single cell
suspension of HUES9 cells were stained with CD34–PerCP and ABCG2 antibodies (left panel). Controls staining with appropriate isotype-matched control mAbs are in the right panel.
Non-viable cells were gated out by Topro3 staining. The remaining OP9 mouse cells were excluded by using Sca-1-FITC labeling.
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Fig. 4. Immunoﬂuorescence detection of pluripotency markers in undifferentiated HuES cells. (A) HUES9 and HUES1 cells were grown on MEF feeder for two days in the eight-well
chamber for confocal microscopy. Co-culture of HuES and MEF cells were ﬁxed and stained with following antibodies: Oct4, SSEA4, PODXL and ABCG2 (green). Undifferentiated
markers stained only the HuES clumps while MEF cells do not show any sign of staining with these markers. Nuclei were counterstained with DAPI (blue). (B) Immunoﬂuorescence
analysis of the ABCG2 expression. The HUES9 cells were cultured and stained with ABCG2 antibody (green) and DAPI (blue) as described above. The plasmamembrane localization of
ABCG2 is clearly shown with this higher magniﬁcation.
Fig. 5. Expression levels of multidrug transporter mRNAs in different cell lines
determined by real-time PCR, using the SYBR green methodology. Results represent the
mean values±S.E.M. of at least three independent measurements; GAPDH mRNA was
used as an internal control. HUE9d-F2: HUES9-derived ﬁbroblast cell line; HL60/ABCC1:
drug resistant, ABCC1 (MRP1) overexpressing cell line.
2705Á. Apáti et al. / Biochimica et Biophysica Acta 1778 (2008) 2700–2709forms of the HuES cells. For human control tissues, we usedmRNA and
the respective cDNA preparations obtained from fetal liver, adult liver
and a drug-resistant leukemia cell line. As shown in Fig. 5, ABCG2
mRNA level was high in the undifferentiated HuES cells and decreased
signiﬁcantly in the differentiated cell types. These data closely
correspond to the level of protein expression demonstrated above.
According to the qPCR results, the ABCB1 (MDR1) mRNA level was low
in all HuES cells examined, while ABCC1 (MRP1) mRNA was quite
uniform and relatively high, both in the HuES and the reference liver
cells. This relatively high level ABCC1-mRNA expression is currently
unexplained, as the ABCC1 protein expression has been documented
to be relatively low in the liver, and we found no traces of
immunostaining or function (see below) of ABCC1 in any HuES cell
types. These results could be caused by the presence of a fewcells with
relatively high ABCC1 expression, causing a discrepancy in the average
mRNA and the protein levels. Alternatively, these data may indicate a
posttranscriptional or negative translational regulation for ABCC1
mRNA in HuES cells.
3.2. Functional studies for ABC transporters in HuES cells
In order to examine the function of the ABCmultidrug transporters
in the HuES cells and in their early differentiated forms, we applied
highly sensitive ﬂuorescent dye transport assays. To avoid misleading
conclusions due to a potential heterogeneity of the HuES cells (see
above), we applied these assays in real-time confocal microscopy
settings (see [25,26]). In living cell samples the respective ﬂuorescent
dye was added to the incubation chamber, and dye uptake was
continuously monitored, ﬁrst without the addition, and then after the
addition of a speciﬁc inhibitor of the respective transporter. Thereafter
the preparationwas gently ﬁxed, and the cells in the HuES clump or in
the various differentiated HuES tissue types were immunostained. The
ﬂuorescent dye uptake was selectively analyzed in the cells expres-
sing, or not expressing the respective transporter.
For the analysis of ABCG2 function we measured the Ko143 (a
selective ABCG2 inhibitor) sensitive extrusion of the Hoechst 33342
(Hst) dye in the HuES cells. This Hst dye is actively extruded by both
the ABCB1/MDR1 and ABCG2 proteins, while Ko143, in the concentra-
tions applied (1 μM), is a fully efﬁcient inhibitor of the ABCG2
transporter [22]. As documented in Fig. 6A–C, undifferentiated HUES9
cells showed an initial low rate, and a Ko143-induced increase in theuptake of the Hst dye, indicating a functional expression of the ABCG2
protein. It is well documented in the numerical analysis (Fig. 6C) of the
time-course of dye uptake that cells with higher ABCG2 expression, as
testiﬁed by higher 5D3 immuno-labeling, showed much greater
Ko143-inhibitable Hst dye extrusion than the cells not stained by
5D3. In this assay there was no measurable effect of 10 μM Verapamil,
which inhibits the ABCB1/MDR1 protein (not shown).
In order to further examine if ABCG2 has a protective role under
the effects of drugs and xenobiotics, we exposed undifferentiated
HuES cells by increasing concentration of mitoxantrone (MX, 1–
20 nM), in the presence or absence of the ABCG2 inhibitor, Ko143.
The HuES cells well tolerated 10 nM MX treatment, but this dose of
MX caused a complete eradication of the colonies in the presence of
the ABCG2 inhibitor. Moreover, during a few days a signiﬁcantly
increased surface expression of ABCG2 was found in the MX-treated
HuES cells (Fig. 6D). There was no measurable change in the MDR1 or
MRP1 expression under these conditions (data not shown).
Fig. 6. Functional analysis of ABCG2 in undifferentiated HuES cells. (A) Clumps of HUES9 cells were grown on MEF feeder layer for one day in the eight-well chamber for confocal
microscopy. The intracellular accumulation of Hst dye in living HUES9 cells was monitored by confocal microscopy. Approx. 2 min after Hst addition, ABCG2-mediated dye extrusion
was blocked by 1 μM Ko143; cell nuclei stained blue at the end of Hst uptake are shown. (B) After Hst uptake measurements the living cells of the same clump were gently ﬁxed and
stained for ABCG2 by 5D3 antibody. Green arrows indicate cells with high expression of ABCG2, while the white arrows show the cells with no expression of ABCG2. (C) Kinetics of
nuclear accumulation of Hst dye. The green curve was calculated from the data of ABCG2 expressing cells (green arrows). The white curve was calculated from the data of cells which
do not express ABCG2 (white arrow). The ABCG2 activity factor (MAF) was calculated in both cases as described in Materials and methods. (D) Flow cytometry measurements of
ABCG2 and SSEA4 expression in undifferentiated (Control) and 10 nM mitoxantrone treated HUES9 cells. Details are discussed in the text; dashed lines show staining with
appropriate isotype-matched control mAbs.
2706 Á. Apáti et al. / Biochimica et Biophysica Acta 1778 (2008) 2700–2709For further functional detection of the ABCB1 and ABCC1 protein in
theHuES cellswe have also carried out Calcein accumulation studies. The
transport activity of both the MDR1 and the MRP1 proteins strongly
reduces the cellular accumulation of the ﬂuorescent Calcein dye, thus the
determination of Calcein uptake with or without speciﬁc inhibitors is a
highly sensitiveprobe for their transport function [24].Without adetailed
documentation of the data obtained,we found nomeasurable increase in
the Calcein accumulation in the HuES cells, either after the addition of
Verapamil (10–60 μM), or in the presence of the ABCC1 inhibitor, MK571.
These experiments suggest again the lack of measurable expression or
function of ABCB1 or ABCC1 in the undifferentiated HuES cells.
3.3. mRNA studies for ABCG2
In order to identify potential ABCG2mRNA species, we conducted a
bioinformatical search in the NCBI Aceview database (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), where 3 distinct
5′-UTR sequences were revealed. We conﬁrmed the existence of three
alternative ABCG2 transcripts, termed a, b and c, by speciﬁcally
designed PCR primers in different cell lines, as well as in HuES cells
(Fig. 7A and B). However, these 3 alternative 5′-UTRs did not
correspond to the sequences described earlier in human cells [17]. In
fact, our exon 1c sequence, detected in dendritic cells and in the CHRF
cell line (representing a distinct stage of megakaryocyte differentia-
tion), is a product of a promoter located far upstream of the 5′
region, which was reported to contain the putative ABCG2
promoters [16]. The location of this new promoter and the type of
tissues expressing this mRNA indicate that our exon 1c could be the
functional/evolutionary equivalent of the mouse hematopoietic-
speciﬁc E1C leader exon [18]. On the other hand, after sequencing
and analyzing the other possible ﬁrst exons, our results imply that
the original exon 1b and 1c, described by Nakanishi et al., are not
Fig. 7. Examination of the 5′- and the 3′-UTRs of the ABCG2 mRNA. (A) Structure of the 5′ promoter regions of the ABCG2 gene. The three mutually exclusive ﬁrst exons are noncoding leader sequences, as the translational start codon (trl start)
is located on exon 2. One of the three forward primers (Fa–Fc) and the reverse primer (R) are used to amplify the corresponding 5′mRNA regions transcribed from a given promoter (for primer sequences, see Materials and methods). Intronic
sequences are not drawn to scale. (B) Alternative promoter usage of ABCG2 in different cell lines. Exon 1a is detected in HuES cell lines and in a mitoxantrone-selected MCF-7 cell line, although the expression level differs signiﬁcantly (see also
Supplementary Fig. 3A). Exon 1c was only identiﬁed in cells corresponding to later stages of hematopoietic differentiation (dendritic cells and CHRF cell line). In contrast, exon 1b is always present when ABCG2 is expressed in a cell and it might
represent the only leader exon as demonstrated in different liver cells (al=adult liver; ﬂ=fetal liver). (C) 3′ structure of the ABCG2 mRNA. The translational stop codon (trl stop) and the alternative 3′ end of the shorter mRNA are located on the
ﬁrst region of exon 16. Two putative unique miRNA binding sites are present in the longer 3′-UTR and one unique miRNA site is predicted in the shorter 3′-UTR. In addition, ⁎ indicates a region where multiple overlapping miRNA sites are
predicted (see text and Supplementary Table 1 for further details). The forward primer (F) and one of the three reverse primers (R1–R3) are used for amplifying the corresponding ABCG2 sequences. Note that only the F-R3 combination detects
the longer 3′-UTR containingmRNA isoform exclusively. For primer sequences, see Materials andmethods. (D) Examining the 3′-UTRs of ABCG2mRNA in different cell lines. Among these cell types, only HUES9 lack the long 3′-UTR variant (3′-
UTR3) with its potential regulatory sequences (see text for more details). The CHRF cell line also seems to have a very low expression of this variant, although this is only a semi-quantitative study.
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leakage of transcription initiation. Therefore we refer to these
overlapping variants jointly as exon 1b, and the sequences resulting
from the activity of the farthest located promoter as exon 1c. In
agreement with the earlier ﬁndings, we could detect the presence of
exon 1a from the usage of the third promoter.
The mRNA variants with different 5′-UTRs most likely encode the
same protein species, although their stability or the presence of
regulatory factor binding sites could be different. In addition, the exon
1a transcript may result in the addition of 30 amino acids to the amino
terminal of the protein via an unconventional translational initiation,
but the existence of such a protein species has not yet been observed.
In all ABCG2 expressing tissues and cell lines the exon 1b variant could
be detected. In contrast, the 1a variant was found in the two HuES cell
lines, and in a mitoxantrone-selected MCF-7 cell line, indicating a
potential role of this mRNA species in high level ABCG2 expression
(Fig. 7B and Supplementary Fig. 3A).
In addition to the alternative promoter variants, we have also
examined the 3′ region of the ABCG2 transcripts. The NCBI Aceview
database predicted two distinct polyadenylation sites and therefore
two different 3′-UTRs (Fig. 7C). PCR experiments with speciﬁcally
designed primers showed that the two predicted mRNA species
indeed exist, although their expression ratio is variable among cell
lines (Fig. 7D). We found that the mitoxantrone-selected MCF-7 cells
and liver cells have ABCG2 transcripts with longer 3′-UTRs, whereas
the HUES cells express mRNA species with a shorter 3′-UTR. For these
patterns different tissue-speciﬁc polyadenylation factors may be
responsible. Still, a short 3′-UTR may cause an increased message
stability for ABCG2, and, indeed, Sandberg et al. [31] found that rapidly
proliferating cells express ABCG2 mRNAs with shorter 3′-UTRs, to
escape miRNA regulation.
A recent paper describes the regulation of ABCG2 transcript
stability via a putative miRNA in a colon cancer cell line [32]. A
prediction analysis concerning potential miRNA target sites in the
miRBase program (http://microrna.sanger.ac.uk/targets/v5/), revealed
multiple hits in the different UTR sequences of ABCG2 (Fig. 7C).
Among the three unique miRNA sites, one (hsa-mir-142-5p) is located
upstream of the short 3′-UTR end, while the other two unique miRNA
sites (for hsa-mir-100 and hsa-mir-519c) are located in the sequence
that is missing from the short 3′-UTR (Fig. 7C). These latter sites may
have regulatory roles only in the long 3′-UTR species. We could also
predict a target sequence upstream of the short 3′ end, which could be
potential binding sites for various miRNAs, and we refer to it as a
common overlapping site (Fig. 7C and Supplementary Table 1—see
http://www.ma.uniheidelberg.de/apps/zmf/argonaute/interface/).
Two of these miRNAs are expressed in HuES cells (hsa-miR-302a and
has-miR-302d), however, further experiments are needed to ﬁnd out
whether they are bona ﬁde regulators of the ABCG2message in human
embryonic stem cells.
In order to provide evidence that the differently combined 5′-/3′-
UTR containing transcripts exist, we attempted to amplify the entire
ABCG2 cDNA by using various combinations of different leader exon
and 3′-UTR speciﬁc primers (Supplementary Fig. 3B) As all tested
combinations were found to exist, this experiment revealed that there
is no tight connection between the 5′- and 3′-UTR formation but rather
they are regulated separately. Taken together, our studies indicate that
ABCG2 mRNA in HUES cells may be under different regulatory control
than in other ABCG2 expressing, differentiated cells.
As a summary, the above described experiments collectively
indicate a selective, high level functional expression of the ABCG2
multidrug transporter in undifferentiated human embryonic stem
cells. At the same time we found a lack of signiﬁcant expression or
function of the other two major drug transporters, ABCB1 or ABCC1.
The parallel changes in the expression of the ABCG2 protein on the
HuES cell surface with acknowledged human markers for undiffer-
entiated cells suggests that ABCG2 may be regarded as a differentia-tion marker, as well as potentially providing a functional protection
against drugs or other harmful cellular effects, e.g. hypoxia. The
further elucidation of ABCG2 regulation in human embryonic stem
cells may help to understand a complex defense of these undiffer-
entiated cell types. We also demonstrate here a special form of the
ABCG2 mRNA in the undifferentiated HuES cells, which suggests a
potential regulation of this ABC transporter at the transcriptional level.
Chemoprotection of stem cells and tumor stem cells may greatly
depend on this ABCG2 regulation, thus the current ﬁndings may have
important relevance to normal and cancerous cell differentiation and
the response of cancer stem cells to chemotherapy.
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